“…Despite the pause, the response rate of the patients was similar, and survival was even longer compared with previous reports with continuous IFN-␣, 5,6,9,25 IFN-␣, and vinblastine 19 and other combination treatments including interleukin-2. 8,11,24,26 A randomized trial previously has indicated that IFN-␣ increases the survival rate of RCC patients. 19,27 In most previous studies, the duration of the treatment with IFN-␣ has been 6 -12 weeks, 5,15,17 and most responses have been observed within 2 or 4 months of treatment start.…”